The β3-Adrenergic System and β3-Adrenergic Agonists

[1] Arch J.R.S., Piercy V., Thurlby P.L., Wilson C., Wilson S., Thermogenic and lipolytic drugs for the treatment of obesity: Old ideas and new possibilities, Recent Advances in Obesity Research. V Edn., pp. 300-311, (1987)

[2] Schiffelers S.L.H., Van Harmelen V.J.A., De Grauw H.A.J., Saris W.H.M., Van Baak M.A., Dobutamine as selective β₁adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization, J Appl Physiol, 87, pp. 977-981, (1999)

[3] Amoroso P., Wilson S.R., Moxham J., Ponte J., Acute effects of inhaled salbutamol on the metabolic rate of normal subjects, Thorax, 48, pp. 882-885, (1993)

[4] Cawthorne M.A., Arch J.R.S., The search for peripherally acting drugs for the treatment of obesity - A review, Int J Obesity, 6, pp. 1-10, (1982)

[5] Astrup A., Breum L., Toubro S., Hein P., Quade F., The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: A double blind trial, Int J Obesity, 16, pp. 269-277, (1992)

[6] Norregaard J., Jorgensen S., Mikkelsen K.L., Tonnesen P., Iversen E., Sorensen T., Soeberg B., Jakobsen H.B., The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain, Clin Pharm Ther, 60, pp. 679-686, (1996)

[7] Holloway B.R., Selective β-agonists of brown fat and thermogenesis, Hormones, Thermogenesis, and Obesity, pp. 477-484, (1989)

[8] Montastruc J.L., Verwaerde P., Pelat M., Galitzky J., Langin D., Lafontan M., Berlan M., Peripheral cardiovascular actions of SR5861IA, a β₃-adrenoceptor agonist, in the dog: Lack of central effect, Fundament Clin Pharmacol, 13, pp. 180-186, (1999)

[9] Shen Y.-T., Cervoni P., Claus T., Vatner S.F., Differences in β₃-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs, J Pharmacol Exp Ther, 278, pp. 1435-1443, (1996)

[10] Hom G.J., Forrest M.J., Bach T.J., Brady E., Candelore M.R., Cascieri M.A., Fletcher D.J., Fisher M.H., Iliff S.A., Mathvink R.J., Metzger J., Pecore V., Saperstein R., Shih T., Weber A.E., Wyrvratt M., Zafian P., MacIntyre D.E., β₃-Adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys, J Pharmacol Exp Ther, 297, pp. 299-307, (2001)

[1] Arch J.R.S., Piercy V., Thurlby P.L., Wilson C., Wilson S., Thermogenic and lipolytic drugs for the treatment of obesity: Old ideas and new possibilities, Recent Advances in Obesity Research. V Edn., pp. 300-311, (1987)

[2] Schiffelers S.L.H., Van Harmelen V.J.A., De Grauw H.A.J., Saris W.H.M., Van Baak M.A., Dobutamine as selective β₁adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization, J Appl Physiol, 87, pp. 977-981, (1999)

[3] Amoroso P., Wilson S.R., Moxham J., Ponte J., Acute effects of inhaled salbutamol on the metabolic rate of normal subjects, Thorax, 48, pp. 882-885, (1993)

[4] Cawthorne M.A., Arch J.R.S., The search for peripherally acting drugs for the treatment of obesity - A review, Int J Obesity, 6, pp. 1-10, (1982)

[5] Astrup A., Breum L., Toubro S., Hein P., Quade F., The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: A double blind trial, Int J Obesity, 16, pp. 269-277, (1992)

[6] Norregaard J., Jorgensen S., Mikkelsen K.L., Tonnesen P., Iversen E., Sorensen T., Soeberg B., Jakobsen H.B., The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain, Clin Pharm Ther, 60, pp. 679-686, (1996)

[7] Holloway B.R., Selective β-agonists of brown fat and thermogenesis, Hormones, Thermogenesis, and Obesity, pp. 477-484, (1989)

[8] Montastruc J.L., Verwaerde P., Pelat M., Galitzky J., Langin D., Lafontan M., Berlan M., Peripheral cardiovascular actions of SR5861IA, a β₃-adrenoceptor agonist, in the dog: Lack of central effect, Fundament Clin Pharmacol, 13, pp. 180-186, (1999)

[9] Shen Y.-T., Cervoni P., Claus T., Vatner S.F., Differences in β₃-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs, J Pharmacol Exp Ther, 278, pp. 1435-1443, (1996)

[10] Hom G.J., Forrest M.J., Bach T.J., Brady E., Candelore M.R., Cascieri M.A., Fletcher D.J., Fisher M.H., Iliff S.A., Mathvink R.J., Metzger J., Pecore V., Saperstein R., Shih T., Weber A.E., Wyrvratt M., Zafian P., MacIntyre D.E., β₃-Adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys, J Pharmacol Exp Ther, 297, pp. 299-307, (2001)